Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

16164 reported adverse events

Drugs of this class: VALGANCICLOVIR GANCICLOVIR

These side effects are most commonly reported by patients taking drugs of the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] class:

# Side effect Count
0 OFF LABEL USE 1965
1 CYTOMEGALOVIRUS INFECTION 1702
2 DRUG INEFFECTIVE 1385
3 PYREXIA 976
4 NEUTROPENIA 871
5 DIARRHOEA 808
6 PRODUCT USE IN UNAPPROVED INDICATION 771
7 LEUKOPENIA 753
8 DRUG RESISTANCE 688
9 CYTOMEGALOVIRUS VIRAEMIA 671
See all common reactions for Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

Drugs of the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CYTOMEGALOVIRUS SYNDROME 78 0.5417
1 ENCEPHALITIS CYTOMEGALOVIRUS 124 0.4247
2 SMOOTH MUSCLE CELL NEOPLASM 94 0.3790
3 CYTOMEGALOVIRUS GASTROINTESTINAL INFECTION 80 0.3448
4 CYTOMEGALOVIRUS OESOPHAGITIS 66 0.2374
5 CYTOMEGALOVIRUS VIRAEMIA 671 0.2178
6 DELAYED GRAFT FUNCTION 119 0.2129
7 CYTOMEGALOVIRUS ENTERITIS 56 0.1993
8 CYTOMEGALOVIRUS CHORIORETINITIS 234 0.1565
9 PARVOVIRUS B19 INFECTION 71 0.1537
See all enriched reactions for Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]